Relationship of Glycemia to Cardiovascular Disease ... - Lipids Online

STOP-NIDDM Trial: Acarbose Prevents Type 2
Diabetes Mellitus and Cardiovascular Events in
Subjects With Impaired Glucose Tolerance
Study Population
Acarbose
n=662
Placebo
n=888
Hazard Ratio
(95% CI)
P
Value
Favors
Acarbose
Favors
Placebo
Myocardial infarction
1
12
0.09 (0.01–0.72)
0.02
Angina
5
12
0.45 (0.16–1.28)
0.13
Revascularization
procedures
11
20
0.61 (0.29–1.26)
0.18
Cardiovascular death
1
2
0.55 (0.05–6.11)
0.63
Congestive heart failure
0
2
Cerebrovascular stroke
2
4
0.56 (0.10–3.07)
0.51
Any cardiovascular
event
15
32
0.51 (0.28–0.95)
0.03
CI = confidence interval
0 0.5 1.0 1.5
Hazard Ratio
Chiasson JL, et al. JAMA. 2003;290;486–494. Copyright © 2003
American Medical Association. All rights reserved.
Slide Source
Lipids Online Slide Library
www.lipidsonline.org
STOP-NIDDM Trial: Acarbose Prevents Type 2 Diabetes Mellitus and
Cardiovascular Events in Subjects With Impaired Glucose Tolerance
Examining the different events between the acarbose and placebo populations in the
STOP-NIDDM trial showed that there were 15 events in the acarbose group and 32
events in the placebo groups, suggesting that a treatment focused on postprandial
hyperglycemia could reduce the risk for cardiovascular events. These intriguing data
await further confirmation and additional studies.
Reference:
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, for the STOP-
NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease
and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
JAMA. 2003;290:486-494.
Source: Lipids Online Slide Library (www.lipidsonline.org) Page 7 of 36
© 2009 Baylor College of Medicine, Houston, Texas